Clinical trial

Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE)

NCT05332561

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2023-06-29

PhasePHASE2

Study timeline

Study start (actual)2023-06-29Date precision: day

Registry last updated2025-03-20

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Early-stage Breast Cancerunresolved

Interventions

Atezolizumab 1200 mg in 20 ML InjectionDRUG · verified · RxNorm: 20 ML atezolizumab 60 MG/ML Injection

InavolisibDRUG · verified · RxNorm: inavolisib

IpatasertibDRUG

OlaparibDRUG · verified · RxNorm: olaparib

Sacituzumab govitecanDRUG · verified · RxNorm: sacituzumab govitecan

Trastuzumab/pertuzumabDRUG

Sponsors & collaborators

German Cancer Research Centerlead sponsor

Mapped research locations

BerlinGermany1 EssenGermany1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05332561 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.